Matinas BioPharma Holdings, Inc. (MTNB)
USD 0.59
(-0.45%)
USD 0.59
(-0.45%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | -13.39 Million USD | 101.15% |
| 2022 | -13.49 Million USD | -1703.1% |
| 2021 | -748.15 Thousand USD | 94.73% |
| 2020 | -14.2 Million USD | -27.42% |
| 2019 | -11.14 Million USD | -67.14% |
| 2018 | -6.66 Million USD | 24.75% |
| 2017 | -8.86 Million USD | -16731.57% |
| 2016 | -52.64 Thousand USD | 98.97% |
| 2015 | -5.09 Million USD | 1.5% |
| 2014 | -5.17 Million USD | 0.0% |
| 2013 | - USD | 0.0% |
| 2012 | - USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | -240 Thousand USD | 82.04% |
| 2024 Q2 | -241 Thousand USD | -0.42% |
| 2023 Q1 | 867 Thousand USD | 135.71% |
| 2023 Q2 | -234 Thousand USD | -126.99% |
| 2023 Q4 | -1.33 Million USD | -461.34% |
| 2023 Q3 | -238 Thousand USD | -1.71% |
| 2023 FY | 155 Thousand USD | 101.15% |
| 2022 Q2 | 832.63 Thousand USD | 493.63% |
| 2022 Q1 | -211.52 Thousand USD | 84.46% |
| 2022 FY | -13.49 Million USD | -1703.1% |
| 2022 Q4 | -2.42 Million USD | -391.93% |
| 2022 Q3 | 831.71 Thousand USD | -0.11% |
| 2021 Q3 | -196.03 Thousand USD | -7.25% |
| 2021 Q4 | -1.36 Million USD | -594.4% |
| 2021 FY | -748.15 Thousand USD | 94.73% |
| 2021 Q2 | -182.78 Thousand USD | 94.3% |
| 2021 Q1 | -3.2 Million USD | -217.48% |
| 2020 FY | -14.2 Million USD | -27.42% |
| 2020 Q3 | -3.24 Million USD | 4.98% |
| 2020 Q2 | -3.41 Million USD | 16.56% |
| 2020 Q1 | -4.08 Million USD | -16.45% |
| 2020 Q4 | -1.01 Million USD | 68.82% |
| 2019 Q3 | -2.67 Million USD | 2.47% |
| 2019 Q1 | -2.31 Million USD | -27.73% |
| 2019 FY | -11.14 Million USD | -67.14% |
| 2019 Q4 | -3.5 Million USD | -31.38% |
| 2019 Q2 | -2.73 Million USD | -18.33% |
| 2018 Q4 | -1.81 Million USD | -31.36% |
| 2018 FY | -6.66 Million USD | 24.75% |
| 2018 Q3 | -1.37 Million USD | 3.72% |
| 2018 Q1 | -2.16 Million USD | 4.02% |
| 2018 Q2 | -1.43 Million USD | 33.75% |
| 2017 Q4 | -2.25 Million USD | -14.5% |
| 2017 FY | -8.86 Million USD | -16731.57% |
| 2017 Q3 | -1.96 Million USD | 13.29% |
| 2017 Q2 | -2.26 Million USD | 4.2% |
| 2017 Q1 | -2.36 Million USD | -427.27% |
| 2016 Q2 | -642.57 Thousand USD | 30.28% |
| 2016 Q4 | 723.95 Thousand USD | 186.67% |
| 2016 Q3 | -835.3 Thousand USD | -29.99% |
| 2016 Q1 | -921.71 Thousand USD | 48.92% |
| 2016 FY | -52.64 Thousand USD | 98.97% |
| 2015 FY | -5.09 Million USD | 1.5% |
| 2015 Q4 | -1.8 Million USD | -120.22% |
| 2015 Q3 | -819.33 Thousand USD | 35.88% |
| 2015 Q2 | -1.27 Million USD | 8.13% |
| 2015 Q1 | -1.39 Million USD | 27.33% |
| 2014 Q1 | -1.07 Million USD | 0.0% |
| 2014 Q4 | -1.91 Million USD | -78.9% |
| 2014 Q2 | -1.11 Million USD | -4.14% |
| 2014 FY | -5.17 Million USD | 0.0% |
| 2014 Q3 | -1.06 Million USD | 4.34% |
| 2013 Q3 | - USD | 0.0% |
| 2013 Q2 | - USD | 0.0% |
| 2013 Q1 | - USD | 0.0% |
| 2013 Q4 | - USD | 0.0% |
| 2013 FY | - USD | 0.0% |
| 2012 FY | - USD | 0.0% |
| 2012 Q4 | - USD | 0.0% |
| 2012 Q3 | - USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| AIM ImmunoTech Inc. | 160 Thousand USD | 8470.625% |
| Ampio Pharmaceuticals, Inc. | -250 Thousand USD | -5257.2% |
| Armata Pharmaceuticals, Inc. | -29.24 Million USD | 54.198% |
| Actinium Pharmaceuticals, Inc. | -709 Thousand USD | -1788.999% |
| Azitra, Inc. | 260.45 Thousand USD | 5242.234% |
| Can-Fite BioPharma Ltd. | 743 Thousand USD | 1902.557% |
| Chromocell Therapeutics Corporation | -2.57 Million USD | -419.226% |
| Calidi Biotherapeutics, Inc. | -1.25 Million USD | -966.322% |
| CEL-SCI Corporation | -3.95 Million USD | -238.349% |
| iBio, Inc. | -1.02 Million USD | -1206.634% |
| Lineage Cell Therapeutics, Inc. | 8.27 Million USD | 261.869% |
| MAIA Biotechnology, Inc. | - USD | Infinity% |
| Navidea Biopharmaceuticals, Inc. | -119.29 Thousand USD | -11126.791% |
| NovaBay Pharmaceuticals, Inc. | 7.89 Million USD | 269.639% |
| NanoViricides, Inc. | -759.01 Thousand USD | -1664.526% |
| Oragenics, Inc. | -15.45 Million USD | 13.33% |
| BiomX Inc. | -1.22 Million USD | -990.635% |
| BiomX Inc. | -1.22 Million USD | -990.635% |
| Protalix BioTherapeutics, Inc. | 42.51 Million USD | 131.504% |
| Palatin Technologies, Inc. | 4.39 Million USD | 404.909% |
| Scorpius Holdings, Inc. | -2.21 Million USD | -504.264% |